Brentuximab Vedotin
Information about Brentuximab Vedotin
Brentuximab Vedotin Uses
Brentuximab Vedotin is used in the treatment of Hodgkin’s disease.
How Brentuximab Vedotin works
Brentuximab Vedotin is a monoclonal antibody that targets a protein called CD30 that is found on certain cancer cells. Brentuximab Vedotin sticks to the CD30 protein and delivers a toxin called monomethyl auristatin E (MMAE) to the cell. This MMAE then kills the cell.
Common side effects of Brentuximab Vedotin
Peripheral neuropathy (tingling and numbness of feet and hand), Fatigue, Nausea, Diarrhea, Decreased white blood cell count (neutrophils), Upper respiratory tract infection, Fever, Constipation, Vomiting, Hair loss, Weight loss, Abdominal pain, Anemia (low number of red blood cells), Stomatitis (Inflammation of the mouth), Lymphopenia, Mucositis, Low blood platelets, Febrile neutropenia
Available Medicine for Brentuximab Vedotin
Expert advice for Brentuximab Vedotin
- Brentuximab Vedotin is a type of targeted cancer drug called a monoclonal antibody.
- You are advised to inform your doctor if you experience any numbness or tingling of the hands or feet or any muscle weakness.
- Contact your doctor if a fever of 100.5°F or greater, cough, chills, severe abdominal pain, or pain on urination develops.
- Contact your doctor if they experience signs and symptoms of infusion reactions including fever, chills, rash, or breathing problems within 24 hours of infusion.
- Brentuximab Vedotin may increase blood glucose level, ask your doctor regarding required precautions.
- Inform your doctor if you experience symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice.
- You must report immediately if you or anyone close to you notice changes in mood or usual behavior, thinking problems, confusion, loss of memory, changes in vision, speech, or walking, or decreased strength or weakness on one side of the body.